Ingelheim, Germany/Ridgefield, Connecticut, U.S. Boehringer Ingelheim’s JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients.2 JASCAYD is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of…

THIS NEWS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Toronto, Ontario and Nucla, Colorado, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Western Uranium & Vanadium Corp. (CSE: WUC) (“Western” or the  ”Company”) is pleased to announce that it has entered into an engagement agreement with A.G.P. Canada…

CALGARY, Alberta, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Brookfield Residential Properties ULC (“Brookfield Residential” or the “Company”) today announced that its 2025 third quarter results will be released after market closes on Wednesday, October 29, 2025. The financial results and information relating to the 2025 third quarter will be posted on the Company’s website at…

SAN FRANCISCO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- A new class action lawsuit is targeting enterprise AI software company C3.ai (NYSE: AI) and its senior leadership, alleging they misled investors about the company's financial health and growth prospects. The suit, filed in the U.S. District Court for the Northern District of California, claims that C3.ai…